Guggenheim cuts Eloxx Pharmaceuticals price target to $40 from $43
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
Hang Seng Tech Index Reverses Losses, Up 1.0% at 3780.34
M impact | EQUITY | Oct 30, 2026, 01:42 AM UTC
Kospi closes 3.96% lower as Asian markets fall
Asian equities fell Friday as technology shares slid for a second session. South Korea’s Kospi led losses, closing 3.96% lower.
M impact | EQUITY | Oct 30, 2026, 01:41 AM UTC
HPQ and Dell Shares Fall After Intel Flags Prolonged PC Weakness
HPQ fell 7.4% in the overnight session after Intel forecast a prolonged slowdown in PC sales; HPQ had already dropped nearly 2% in the regular session.
M impact | EQUITY | Oct 30, 2026, 01:41 AM UTC
China AI Chipmaker Denglin Technology Plans Hong Kong IPO
Hong Kong listing documents say Denglin Technology, a Chinese GPGPU provider, plans to raise funds. The headline reports six Hong Kong IPOs.
L impact | EQUITY | Oct 30, 2026, 01:40 AM UTC
McPherson's Q1 Sales Fall 11% Below Prior Corresponding Period
McPherson's reported Q1 sales 11% below the prior corresponding period.
M impact | EQUITY | Oct 30, 2026, 01:37 AM UTC
Galan Lithium Targets First LiCl Sales in Q4 2026, Begins Expansion
Galan said HMW Phase 1 remains on track for first lithium chloride concentrate sales in Q4 CY2026 and began earthworks for an expansion to 5.2 ktpa LCE. Initial 4 ktpa throughput i
M impact | EQUITY | Oct 30, 2026, 01:37 AM UTC